date,title,source
Oct-18-18,"Detailed Research: Economic Perspectives on Control4, REGENXBIO, Ferro, Kadmon, Hemispherx BioPharma, and Murphy Oil  What Drives Growth in Today's Competitive Landscape",GlobeNewswire
Oct-22-18,REGENXBIO Announces Exclusive Worldwide License with Ultragenyx for the Treatment of CDKL5 Deficiency Disorder Using NAV Vectors,PR Newswire
Oct-26-18,REGENXBIO Announces Additional Positive Interim Phase I Trial Update for RGX-314 for the Treatment of Wet AMD at the American Academy of Ophthalmology 2018 Annual Meeting,PR Newswire
Oct-29-18,ANIK vs. RGNX: Which Stock Should Value Investors Buy Now?,Zacks
Oct-31-18,REGENXBIO to Host Conference Call on November 7 to Discuss Third Quarter 2018 Financial Results and Recent Operational Highlights,PR Newswire
Nov-05-18,REGENXBIO and Abeona Therapeutics Announce Worldwide Exclusive Licenses for the Treatment of Four Rare Lysosomal Storage Disorders Using NAV AAV9 Vector,PR Newswire
